alt

Managing Subacute Bowel Obstruction in Oncology Pa

Shared on November 18, 2026

Palliative Care Case Workshop: Bowel Obstruction and Medication Decisions

Overview

A clinical teaching session on interpreting a bowel obstruction case and selecting or adjusting medicines for a patient with advanced cancer. Key topics include obstruction type, antiemetic choice, renal impairment, opioid conversion, and identifying the likely cause of dry mouth.

Key Concepts

  • “Complete” and “subacute” bowel obstruction are contradictory descriptions in this context: subacute indicates a partial obstruction, while complete means total blockage. Check clinical documentation for internal inconsistencies.
  • A tumour physically compressing the bowel causes a mechanical obstruction. A functional obstruction results from impaired gut movement, such as from nerve dysfunction.
  • Medication choices must account for the obstruction, renal function, route of administration, and side-effect profile.
  • Opioid conversion guidance varies. Apply the relevant guideline and consider patient-specific factors rather than treating dose conversions as exact.

Detailed Notes

Bowel obstruction and antiemetics

  • For the case, the obstruction was treated as complete and mechanical, caused by the cancer mass compressing the bowel.
  • Suitable antiemetic options identified were cyclizine or haloperidol; in this case, treatment was later changed to haloperidol, which was easier to administer via a syringe driver.
  • Avoid metoclopramide and domperidone because their prokinetic effects can increase gut motility against an obstruction.
  • Ondansetron is not prokinetic, but its constipating effect makes it undesirable in this situation.
  • Antiemetics may be administered by subcutaneous infusion when the patient is nil by mouth.

Renal impairment

  • The calculated creatinine clearance was 24.5 mL/min.
  • The creatinine increase was attributed to likely tumour compression of a ureter. Obstructed urine flow can cause urine to back up into the kidney, leading to swelling and kidney damage.
  • Cyclizine or haloperidol may still be used with renal impairment, but the guidance is to start at a low dose and titrate cautiously.

Opioid conversion

  • The patient’s oral modified-release morphine dose was 50 mg twice daily, or 100 mg in 24 hours.
  • In the workshop’s conversion method, divide the 24-hour morphine dose by three to estimate subcutaneous oxycodone: 100 ÷ 3 = 33.3 mg.
  • After applying the case-specific renal adjustment of 75%, the suggested syringe-driver dose was approximately 25 mg of subcutaneous oxycodone over 24 hours.

The session contrasted this method with general BNF guidance, which gives a higher direct equivalent of approximately 50 mg oxycodone for 100 mg morphine, followed by a 25–50% dose reduction when switching opioids. The palliative care guideline incorporates a dose reduction into its conversion approach. In practice, follow the applicable guidance and account for factors such as age, frailty, pain control, opioid tolerance, and prior tolerability.

Dry mouth

  • Haloperidol was considered the most likely cause of the patient’s new dry mouth because it is more strongly associated with this effect.
  • Oxycodone could contribute, but morphine and oxycodone generally have similar opioid side-effect profiles; the change in opioid alone was considered a less likely explanation.

Next case

The workshop then moved to a lung cancer case. Participants were advised that the answer to its first question was not heart failure. A later question required both a new patch dose and the accompanying as-needed (PRN) dose.

Browse all public notes